Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 4
Submit an article Journal homepage
101
Views
0
CrossRef citations to date
0
Altmetric
Review

Killer Artificial Antigen-Presenting Cells: The Synthetic Embodiment of a ‘Guided Missile‘

Christian Schütz1 Department of Internal Medicine I, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93042Regensburg, GermanyCorrespondence[email protected]
View further author information
,
Mathias Oelke2 Johns Hopkins University School of Medicine, MD, USAView further author information
,
Jonathan P Schneck2 Johns Hopkins University School of Medicine, MD, USAView further author information
,
Andreas Mackensen3 Department of Internal Medicines 5, University of Erlangen-Nuernberg, Erlangen, GermanyView further author information
&
Martin Fleck1 Department of Internal Medicine I, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93042Regensburg, GermanyView further author information
Pages 539-550 | Published online: 16 Jul 2010

Bibliography

  • Euvrard S , KanitakisJ, ClaudyA: Skin cancers after organ transplantation.N. Engl. J. Med.348(17) , 1681–1691 (2003).
  • Tanaka Y : B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases.Yakugaku Zasshi129(6) , 675–679 (2009).
  • Lawton JA , GhoshP: Novel therapeutic strategies based on Toll-like receptor signaling.Curr. Opin. Chem. Biol.7(4) , 446–451 (2003).
  • Polman CH , O‘ConnorPW, HavrdovaEet al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med.354(9) , 899–910 (2006).
  • Coles AJ , CompstonDA, SelmajKWet al.: Alemtuzumab vs interferon β-1a in early multiple sclerosis.N. Engl. J. Med.359(17) , 1786–1801 (2008).
  • Kremer JM , DougadosM, EmeryPet al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial.Arthritis Rheum.52(8) , 2263–2271 (2005).
  • Fink PJ , ShimonkevitzRP, BevanMJ: Veto cells.Annu. Rev. Immunol.6 , 115–137 (1988).
  • Tykocinski ML , KaplanDR, MedofME: Antigen-presenting cell engineering. The molecular toolbox.Am. J. Pathol.148(1) , 1–16 (1996).
  • Lu L , LeeWC, TakayamaTet al.: Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4IG).J. Leukoc. Biol.66(2) , 293–296 (1999).
  • Hackstein H , MorelliAE, ThomsonAW: Designer dendritic cells for tolerance induction: guided not misguided missiles.Trends Immunol.22(8) , 437–442 (2001).
  • Kosiewicz MM , KrishnanA, WorthingtonMT, MatrianoJA, RossWG: B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo.Eur. J. Immunol.32(6) , 1679–1687 (2002).
  • Zhang HG , SuX, LiuDet al.: Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.J. Immunol.162(3) , 1423–1430 (1999).
  • Buonocore S , PaulartF, Le Moine A et al.: Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood101(4) , 1469–1476 (2003).
  • Kim SH , KimS, OliginoTJ, RobbinsPD: Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL.Mol. Ther.6(5) , 584–590 (2002).
  • Walczak H , KrammerPH: The CD95 (Apo-1/Fas) and the TRAIL (Apo-2L) apoptosis systems.Exp. Cell. Res.256(1) , 58–66 (2000).
  • Min WP , GorczynskiR, HuangXYet al.: Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.J. Immunol.164(1) , 161–167 (2000).
  • Kusuhara M , MatsueK, EdelbaumD, LoftusJ, TakashimaA, MatsueH: Killing of naive T cells by CD95L-transfected dendritic cells (DC): in vivo study using killer DC–DC hybrids and CD4+ T cells from DO11.10 mice.Eur. J. Immunol.32(4) , 1035–1043 (2002).
  • Matsue H , MatsueK, KusuharaMet al.: Immunosuppressive properties of CD95L-transduced “killer” hybrids created by fusing donor- and recipient-derived dendritic cells.Blood98(12) , 3465–3472 (2001).
  • Chuang YH , SuenJL, ChiangBL: Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma.J. Mol. Med.84(7) , 595–603 (2006).
  • Matsue H , MatsueK, WaltersM, OkumuraK, YagitaH, TakashimaA: Induction of antigen-specific immunosuppression by CD95L cDNA-transfected ‘killer‘ dendritic cells.Nat. Med.5(8) , 930–937 (1999).
  • Wolfe T , AssemanC, HughesA, MatsueH, TakashimaA, Von Herrath MG: Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J. Immunol.169(9) , 4867–4872 (2002).
  • Wu B , WuJM, MiagkovA, AdamsRN, LevitskyHI, DrachmanDB: Specific immunotherapy by genetically engineered APCs: the ‘guided missile‘ strategy.J. Immunol.166(7) , 4773–4779 (2001).
  • Zhang HG , FleckM, KernERet al.: Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice.J. Clin. Invest.105(6) , 813–821 (2000).
  • Wu JM , WuB, MiagkovA, AdamsRN, DrachmanDB: Specific immunotherapy of experimental myasthenia gravis in vitro: the “guided missile” strategy.Cell. Immunol.208(2) , 137–147 (2001).
  • Hoves S , KrauseSW, HalbritterDet al.: Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.J. Immunol.170(11) , 5406–5413 (2003).
  • Hoves S , KrauseSW, HerfarthHet al.: Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing killer-dendritic cells.Immunobiology208(5) , 463–475 (2004).
  • Dulat HJ , Von Grumbkow C, Baars W, Schröder N, Wonigeit K, Schwinzer R: Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur. J. Immunol.31(7) , 2217–2226 (2001).
  • Strauss G , OsenW, KnapeI, JacobsenEM, MullerSM, DebatinKM: Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.Cell Death. Differ.14(3) , 480–488 (2006).
  • Georgantas RW III, Leong KW, August JT: Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum. Gene Ther.11(6) , 851–858 (2000).
  • Whartenby KA , StraleyEE, KimHet al.: Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.Blood100(9) , 3147–3154 (2002).
  • Elhalel MD , HuangJH, SchmidtW, RachmilewitzJ, TykocinskiML: CTLA-4. FasL induces alloantigen-specific hyporesponsiveness.J. Immunol.170(12) , 5842–5850 (2003).
  • Yolcu ES , AskenasyN, SinghNP, CherradiSE, ShirwanH: Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection.Immunity17(6) , 795–808 (2002).
  • Yagita H , SeinoK, KayagakiN, OkumuraK: CD95 ligand in graft rejection.Nature379(6567) , 682 (1996).
  • Lau HT , YuM, FontanaA, StoeckertCJ Jr: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science273(5271) , 109–112 (1996).
  • Zhang J , RoschkeV, BakerKPet al.: Cutting edge: a role for B-lymphocyte stimulator in systemic lupus erythematosus.J. Immunol.166(1) , 6–10 (2001).
  • Askenasy N , YolcuES, YanivI, ShirwanH: Induction of tolerance using Fas ligand: a double-edged immunomodulator.Blood105(4) , 1396–1404 (2005).
  • Symes JC , SiatskasC, FowlerDH, MedinJA: Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.Cancer Gene Ther.16(5) , 439–452 (2009).
  • Hermans IF , RitchieDS, YangJ, RobertsJM, RoncheseF: CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.J. Immunol.164(6) , 3095–3101 (2000).
  • Constantin CM , BonneyEE, AltmanJD, StricklandOL: Major histocompatibility complex (MHC) tetramer technology: an evaluation.Biol. Res. Nurs.4(2) , 115–127 (2002).
  • Prakken B , WaubenM, GeniniDet al.: Artificial antigen-presenting cells as a tool to exploit the immune ‘synapse‘.Nat. Med.6(12) , 1406–1410 (2000).
  • Dal Porto J , JohansenTE, CatipovicBet al.: A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.Proc. Natl Acad. Sci. USA90(14) , 6671–6675 (1993).
  • Maile R , WangB, SchoolerW, MeyerA, CollinsEJ, FrelingerJA: Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers.J. Immunol.167(7) , 3708–3714 (2001).
  • Yuan RR , WongP, McdevittMRet al.: Targeted deletion of T-cell clones using a-emitting suicide MHC tetramers.Blood104(8) , 2397–2402 (2004).
  • Hess PR , BarnesC, WoolardMDet al.: Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin.Blood109(8) , 3300–3307 (2007).
  • Yee C , ThompsonJA, ByrdDet al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.Proc. Natl Acad. Sci. USA99(25) , 16168–16173 (2002).
  • Mackensen A , MeidenbauerN, VoglS, LaumerM, BergerJ, AndreesenR: Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.J. Clin. Oncol.24(31) , 5060–5069 (2006).
  • Hunder NN , WallenH, CaoJet al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.N. Engl. J. Med.358(25) , 2698–2703 (2008).
  • Bollard CM , AguilarL, StraathofKCet al.: Cytotoxic T lymphocyte therapy for Epstein–Barr virus + Hodgkin‘s disease.J. Exp. Med.200(12) , 1623–1633 (2004).
  • Maus MV , ThomasAK, LeonardDGet al.: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.Nat. Biotechnol.20(2) , 143–148 (2002).
  • Sasawatari S , TadakiT, IsogaiM, TakaharaM, NiedaM, KakimiK: Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC.Immunol. Cell. Biol.84(6) , 512–521 (2006).
  • Zappasodi R , Di Nicola M, Carlo-Stella C et al.: The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica93(10) , 1523–1534 (2008).
  • Tham EL , JensenPL, MescherMF: Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-FC proteins.J. Immunol. Methods249(1–2) , 111–119 (2001).
  • Maus MV , RileyJL, KwokWW, NepomGT, JuneCH: HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.Clin. Immunol.106(1) , 16–22 (2003).
  • Oelke M , MausMV, DidianoD, JuneCH, MackensenA, SchneckJP: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.Nat. Med.9(5) , 619–624 (2003).
  • Levine BL , CotteJ, Small Cc et al.: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother.7(5) , 437–448 (1998).
  • Latouche JB , SadelainM: Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.Nat. Biotechnol.18(4) , 405–409 (2000).
  • Oelke M , KruegerC, SchneckJP: Technological advances in adoptive immunotherapy.Drugs Today (Barc.)41(1) , 13–21 (2005).
  • Ugel S , ZosoA, De Santo C et al.: In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res.69(24) , 9376–9384 (2009).
  • Schütz C , FischerK, VolklSet al.: A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogeneous T cell populations.J. Immunol. Methods344(2) , 98–108 (2009).
  • Schütz C , FleckM, MackensenAet al.: Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.Blood111(7) , 3546–3552 (2008).
  • Vanderlugt CL , MillerSD: Epitope spreading in immune-mediated diseases: implications for immunotherapy.Nat. Rev. Immunol.2(2) , 85–95 (2002).
  • Nakayama M , AbiruN, MoriyamaHet al.: Prime role for an insulin epitope in the development of Type 1 diabetes in Nod mice.Nature435(7039) , 220–223 (2005).
  • Krishnamurthy B , DudekNL, MckenzieMDet al.: Responses against islet antigens in nod mice are prevented by tolerance to proinsulin but not IGRP.J. Clin. Invest.116(12) , 3258–3265 (2006).
  • Hild WA , BreunigM, GoepferichA: Quantum dots – nano-sized probes for the exploration of cellular and intracellular targeting.Eur. J. Pharm. Biopharm.68(2) , 153–168 (2008).
  • Van Rensen AJ , WaubenMH, Grosfeld-StulemeyerMC, Van Eden W, Crommelin DJ: Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. Pharm. Res.16(2) , 198–204 (1999).
  • Giannoni F , BarnettJ, BiKet al.: Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane.J. Immunol.174(6) , 3204–3211 (2005).
  • Nagata S : Apoptosis by death factor.Cell88(3) , 355–365 (1997).
  • Shen HM , PervaizS: TNF receptor superfamily-induced cell death: redox-dependent execution.FASEB J.20(10) , 1589–1598 (2006).
  • Fife BT , PaukenKE, EagarTNet al.: Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.Nat. Immunol.10(11) , 1185–1192 (2009).
  • Hirata S , SenjuS, MatsuyoshiH, FukumaD, UemuraY, NishimuraY: Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with trail or programmed death-1 ligand.J. Immunol.174(4) , 1888–1897 (2005).
  • Peakman M , DayanCM: Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?Immunology104(4) , 361–366 (2001).
  • Pittet MJ , GatiA, Le Gal FA et al.: Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J. Immunol.176(4) , 2330–2336 (2006).
  • Weng X , LuS, ZhongMet al.: Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1–FC fusion protein.J. Leukoc. Biol.85(3) , 574–581 (2009).
  • Godfrey WR , KrampfMR, TaylorPA, BlazarBR: Ex vivo depletion of alloreactive cells based on cfse dye dilution, activation antigen selection, and dendritic cell stimulation.Blood103(3) , 1158–1165 (2004).
  • Blanco B , Perez-SimonJA, Sanchez-AbarcaLIet al.: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.Blood107(9) , 3575–3583 (2006).
  • Strauss G , OsenW, KnapeI, JacobsenEM, MullerSM, DebatinKM: Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.Cell Death Differ.14(3) , 480–488 (2007).
  • Panina-Bordignon P , LangR, Van Endert PM et al.: Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J. Exp. Med.181(5) , 1923–1927 (1995).
  • Ouyang Q , StandiferNE, QinHet al.: Recognition of HLA class I-restricted β-cell epitopes in Type 1 diabetes.Diabetes55(11) , 3068–3074 (2006).
  • Takahashi K , HoneymanMC, HarrisonLC: Cytotoxic T cells to an epitope in the islet autoantigen IA-2 are not disease-specific.Clin. Immunol.99(3) , 360–364 (2001).
  • Standifer NE , OuyangQ, PanagiotopoulosCet al.: Identification of novel HLA-A*0201-restricted epitopes in recent-onset Type 1 diabetic subjects and antibody-positive relatives.Diabetes55(11) , 3061–3067 (2006).
  • Panagiotopoulos C , QinH, TanR, VerchereCB: Identification of a β-cell-specific HLA class I restricted epitope in Type 1 diabetes.Diabetes52(11) , 2647–2651 (2003).
  • Jarchum I , NicholL, TruccoM, SantamariaP, DilorenzoTP: Identification of novel IGRP epitopes targeted in Type 1 diabetes patients.Clin. Immunol.127(3) , 359–365 (2008).
  • Takaki T , MarronMP, MathewsCEet al.: HLA-A*0201-restricted T cells from humanized nod mice recognize autoantigens of potential clinical relevance to Type 1 diabetes.J. Immunol.176(5) , 3257–3265 (2006).
  • Hassainya Y , Garcia-PonsF, KratzerRet al.: Identification of naturally processed HLA-A2-restricted proinsulin epitopes by reverse immunology.Diabetes54(7) , 2053–2059 (2005).
  • Toma A , HaddoukS, BriandJPet al.: Recognition of a subregion of human proinsulin by class I-restricted T cells in Type 1 diabetic patients.Proc. Natl Acad. Sci. USA102(30) , 10581–10586 (2005).
  • Pinkse GG , TysmaOH, BergenCAet al.: Autoreactive CD8 T cells associated with b cell destruction in Type 1 diabetes.Proc. Natl Acad. Sci. USA102(51) , 18425–18430 (2005).
  • van Endert P , HassainyaY, LindoVet al.: HLA class I epitope discovery in Type 1 diabetes.Ann. NY Acad. Sci.1079 , 190–197 (2006).
  • Zang YC , LiS, RiveraVMet al.: Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis.J. Immunol.172(8) , 5120–5127 (2004).
  • Berthelot L , LaplaudDA, PettreSet al.: Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.Eur. J. Immunol.38(7) , 1889–1899 (2008).
  • Tsuchida T , ParkerKC, TurnerRV, McfarlandHF, ColiganJE, BiddisonWE: Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides.Proc. Natl Acad. Sci. USA91(23) , 10859–10863 (1994).
  • Biddison WE , TaubDD, CruikshankWW, CenterDM, ConnorEW, HonmaK: Chemokine and matrix metalloproteinase secretion by myelin proteolipid protein-specific CD8+ T cells: potential roles in inflammation.J. Immunol.158(7) , 3046–3053 (1997).
  • Dressel A , ChinJL, SetteA, GauslingR, HollsbergP, HaflerDA: Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands.J. Immunol.159(10) , 4943–4951 (1997).
  • Niland B , BankiK, BiddisonWE, PerlA: CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168–176 in patients with multiple sclerosis.J. Immunol.175(12) , 8365–8378 (2005).
  • Kita H , LianZX, Van De Water J et al.: Identification of HLA-A2-restricted CD8+ cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J. Exp. Med.195(1) , 113–123 (2002).
  • Matsumura S , KitaH, HeXSet al.: Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis.Hepatology36(5) , 1125–1134 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.